JP2003524368A - ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 - Google Patents

ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白

Info

Publication number
JP2003524368A
JP2003524368A JP2000507818A JP2000507818A JP2003524368A JP 2003524368 A JP2003524368 A JP 2003524368A JP 2000507818 A JP2000507818 A JP 2000507818A JP 2000507818 A JP2000507818 A JP 2000507818A JP 2003524368 A JP2003524368 A JP 2003524368A
Authority
JP
Japan
Prior art keywords
domain
nucleic acid
fusion protein
bundling
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000507818A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003524368A5 (enExample
Inventor
ネイトサン，スリダラン
ズィー ギルマン，マイケル
Original Assignee
アリアド ジーン セラピューティクス インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/920,610 external-priority patent/US6015709A/en
Priority claimed from PCT/US1997/015219 external-priority patent/WO1999010508A1/en
Application filed by アリアド ジーン セラピューティクス インコーポレイテッド filed Critical アリアド ジーン セラピューティクス インコーポレイテッド
Publication of JP2003524368A publication Critical patent/JP2003524368A/ja
Publication of JP2003524368A5 publication Critical patent/JP2003524368A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/67—General methods for enhancing the expression
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/37—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi
    • C07K14/39—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from fungi from yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1055—Protein x Protein interaction, e.g. two hybrid selection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Toxicology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2000507818A 1997-08-26 1998-08-26 ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 Pending JP2003524368A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US91840197A 1997-08-26 1997-08-26
US08/918,401 1997-08-26
US08/920,610 US6015709A (en) 1997-08-26 1997-08-27 Transcriptional activators, and compositions and uses related thereto
PCT/US1997/015219 WO1999010508A1 (en) 1997-08-27 1997-08-27 Chimeric transcriptional activators and compositions and uses related thereto
US08/920,610 1997-08-27
US9715219 1997-08-27
US12600998A 1998-07-29 1998-07-29
US09/126,009 1998-07-29
PCT/US1998/017723 WO1999010510A2 (en) 1997-08-26 1998-08-26 Fusion proteins comprising a dimerization, trimerization or tetramerization domain and an additional heterologous transcription activation, transcription repression, dna binding or ligand binding domain

Publications (2)

Publication Number Publication Date
JP2003524368A true JP2003524368A (ja) 2003-08-19
JP2003524368A5 JP2003524368A5 (enExample) 2006-01-05

Family

ID=27492886

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000507818A Pending JP2003524368A (ja) 1997-08-26 1998-08-26 ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白

Country Status (6)

Country Link
US (1) US6117680A (enExample)
EP (1) EP1017829A2 (enExample)
JP (1) JP2003524368A (enExample)
AU (1) AU9036198A (enExample)
CA (1) CA2300376A1 (enExample)
WO (1) WO1999010510A2 (enExample)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6972193B1 (en) * 1993-02-12 2005-12-06 Board Of Trustees Of Leland Stanford Junior University Regulated transcription of targeted genes and other biological events
US6891021B2 (en) * 1993-02-12 2005-05-10 Board Of Trustees Of The Leland Stanford Junior University Regulated apoptosis
JP2002544285A (ja) * 1999-05-14 2002-12-24 メディカル リサーチ カウンシル オリゴマーシャペロンタンパク質
WO2000069907A1 (en) * 1999-05-14 2000-11-23 Medical Research Council Protein scaffold and its use to multimerise monomeric polypeptides
WO2000071743A1 (fr) * 1999-05-25 2000-11-30 Eisai Co., Ltd. Methode bihybride dans une cellule de mammifere
US6537540B1 (en) * 1999-05-28 2003-03-25 Targeted Genetics Corporation Methods and composition for lowering the level of tumor necrosis factor (TNF) in TNF-associated disorders
EP1181360A1 (en) * 1999-05-28 2002-02-27 Sangamo Biosciences Inc. Molecular switches
US7057015B1 (en) 1999-10-20 2006-06-06 The Salk Institute For Biological Studies Hormone receptor functional dimers and methods of their use
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
EP1254179A4 (en) 2000-01-24 2005-06-01 Univ Columbia IN VIVO SCREEN USING CHEMICAL INDUCTORS
US20040033600A1 (en) 2001-03-21 2004-02-19 Palli Subba Reddy Ecdysone receptor-based inducible gene expression system
WO2001070816A2 (en) * 2000-03-22 2001-09-27 Rohm And Haas Company Ecdysone receptor-based inducible gene expression system
IL152871A0 (en) * 2000-06-16 2003-06-24 Ariad Gene Therapeutics Inc Chimeric hsf transcription factors
EP1908835A3 (en) * 2000-07-18 2008-06-18 Novartis AG Regulation of gene expression using single-chain, monomeric, ligand dependent polypeptide switches
US7011972B2 (en) 2000-07-18 2006-03-14 The Scripps Research Institute Fusion polypeptide comprising two ligand binding domains
IL154059A0 (en) * 2000-07-21 2003-07-31 Syngenta Participations Ag Zinc finger domain recognition code and uses thereof
US8105825B2 (en) 2000-10-03 2012-01-31 Intrexon Corporation Multiple inducible gene regulation system
US6576422B1 (en) * 2000-10-17 2003-06-10 Rohm And Haas Company Method for identifying products employing gene expression
ES2385598T3 (es) 2001-02-20 2012-07-27 Intrexon Corporation Sistema novedoso de expresión génica inducible basado en el receptor de ecdisona/receptor X retinoide de invertebrado
EP1534738B1 (en) 2001-02-20 2012-06-20 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
CA2438119C (en) 2001-02-20 2014-12-16 Rheogene Holdings, Inc. Chimeric retinoid x receptors and their use in a novel ecdysone receptor-based inducible gene expression system
AU2002306550B2 (en) 2001-02-20 2007-10-25 Intrexon Corporation Novel substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
ATE497603T1 (de) 2001-03-02 2011-02-15 Gpc Biotech Ag Drei-hybrid-assaysystem
US20040224385A1 (en) * 2001-08-20 2004-11-11 Barbas Carlos F Zinc finger binding domains for cnn
US6858429B2 (en) * 2001-08-23 2005-02-22 The Regents Of The University Of California Universal light-switchable gene promoter system
WO2003020906A2 (en) * 2001-08-31 2003-03-13 Abmaxis, Inc. Multivalent protein conjugate with multiple ligand-binding domains of receptors
JP2005532781A (ja) 2001-09-26 2005-11-04 レオジーン・ホールディングス，インコーポレーテッド ヨコバイエクジソン受容体核酸、ポリペプチド、およびそれらの使用
CA2462598A1 (en) * 2001-10-01 2003-04-10 Bioimage A/S A method of detecting intracellular protein-protein interactions using three heterologous conjugates
US8765408B2 (en) 2002-01-23 2014-07-01 Wisconsin Alumni Research Foundation Prophage element-free bacteria
US20060270043A1 (en) * 2002-01-23 2006-11-30 Blattner Frederick R Bacteria with reduced genome
US8119365B2 (en) * 2002-01-23 2012-02-21 Wisconsin Alumni Research Foundation Insertion sequence-free bacteria
US6989265B2 (en) * 2002-01-23 2006-01-24 Wisconsin Alumni Research Foundation Bacteria with reduced genome
US8039243B2 (en) * 2002-01-23 2011-10-18 Wisconsin Alumni Research Foundation Insertion sequence-free bacteria
EP1478648B1 (en) 2002-02-01 2014-04-30 ARIAD Pharmaceuticals, Inc. Phosphorus-containing compounds and uses thereof
US6845929B2 (en) * 2002-03-22 2005-01-25 Ali Dolatabadi High efficiency nozzle for thermal spray of high quality, low oxide content coatings
US7083918B2 (en) 2002-04-24 2006-08-01 The Trustees Of Columbia University In The City Of New York Bacterial small-molecule three-hybrid system
CA2485939C (en) * 2002-05-29 2013-10-29 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US8673589B2 (en) 2002-05-29 2014-03-18 Regeneron Pharmaceuticals, Inc. Inducible eukaryotic expression system
US7303906B2 (en) * 2002-09-06 2007-12-04 Wisconsin Alumni Research Foundation Competent bacteria
EP1563298A4 (en) * 2002-11-05 2006-12-20 Regeneron Pharma METHODS OF ISOLATING ACTIVE COMPOUNDS AND ACTIVATED TARGETS
US7385027B2 (en) * 2003-01-07 2008-06-10 University Of Kentucky Research Foundation Membrane-permeable peptide capable of calpain inhibition
US7304161B2 (en) 2003-02-10 2007-12-04 Intrexon Corporation Diaclhydrazine ligands for modulating the expression of exogenous genes in mammalian systems via an ecdysone receptor complex
US7456315B2 (en) 2003-02-28 2008-11-25 Intrexon Corporation Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
US20050136035A1 (en) * 2003-06-03 2005-06-23 Derek Ko Cell specific replication-competent viral vectors comprising a self processing peptide cleavage site
WO2005017149A1 (en) * 2003-06-03 2005-02-24 Cell Genesys, Inc. Compositions and methods for enhanced expression of recombinant polypeptides from a single vector using a peptide cleavage site
US7935510B2 (en) 2004-04-30 2011-05-03 Intrexon Corporation Mutant receptors and their use in a nuclear receptor-based inducible gene expression system
EP1765846A4 (en) * 2004-07-13 2010-02-17 Cell Genesys Inc AAV VECTOR COMPOSITIONS AND ITS USE IN PROCESSES FOR INCREASING IMMUNOGLOBULIN EXPRESSION
US7632509B2 (en) 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
US20070292922A1 (en) * 2006-03-31 2007-12-20 Cell Genesys, Inc. Regulated expression of recombinant proteins from adeno-associated viral vectors
US20090136465A1 (en) 2007-09-28 2009-05-28 Intrexon Corporation Therapeutic Gene-Switch Constructs and Bioreactors for the Expression of Biotherapeutic Molecules, and Uses Thereof
EP2550359B1 (en) 2010-03-23 2017-08-09 Intrexon Corporation Vectors conditionally expressing therapeutic proteins, host cells comprising the vectors, and uses thereof
WO2011126808A2 (en) 2010-03-29 2011-10-13 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
US9315825B2 (en) 2010-03-29 2016-04-19 The Trustees Of The University Of Pennsylvania Pharmacologically induced transgene ablation system
EP2681327B1 (en) 2011-03-04 2018-11-21 Intrexon Corporation Vectors conditionally expressing protein
EP3699286A1 (en) 2011-04-20 2020-08-26 The Trustees of the University of Pennsylvania Regimens and compositions for aav-mediated passive immunization of airborne pathogens
US10246503B2 (en) * 2012-12-24 2019-04-02 Beijing Anxinhuaide Biotech. Co., Ltd. Method of improving the pharmacokinetic profile of a therapeutic polypeptide and the use thereof
ES2683329T3 (es) 2013-03-15 2018-09-26 Intrexon Corporation Diacilhidrazinas que contienen boro
US9719106B2 (en) 2013-04-29 2017-08-01 The Trustees Of The University Of Pennsylvania Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereof
EP3613854A1 (en) * 2014-03-05 2020-02-26 National University Corporation Kobe University Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
EP3194359B1 (en) 2014-09-17 2020-04-08 Intrexon Corporation Boron-containing diacylhydrazine compounds
JP6153180B2 (ja) * 2014-11-04 2017-06-28 国立大学法人神戸大学 脱塩基反応により標的化したｄｎａ配列に特異的に変異を導入する、ゲノム配列の改変方法、並びにそれに用いる分子複合体
WO2016200543A2 (en) 2015-05-13 2016-12-15 The Trustees Of The University Of Pennsylvania Aav-mediated expression of anti-inluenza antibodies and methods of use thereof
AU2016334401A1 (en) 2015-10-10 2018-04-26 Intrexon Corporation Improved therapeutic control of proteolytically sensitive, destabilized forms of interleukin-12
US20180230489A1 (en) 2015-10-28 2018-08-16 Voyager Therapeutics, Inc. Regulatable expression using adeno-associated virus (aav)
CN108495932B (zh) 2015-11-27 2022-08-09 国立大学法人神户大学 用于特异性转换靶向dna序列的核酸碱基的单子叶植物的基因组序列的转换方法、及其使用的分子复合体
IL262207B2 (en) 2016-04-15 2026-01-01 Univ Pennsylvania Preparations for the treatment of wet age-related macular degeneration
UY37343A (es) 2016-07-25 2018-02-28 Intrexon Corp Control del fenotipo en plantas
AU2017359342B2 (en) 2016-11-09 2022-02-17 Intrexon Corporation Frataxin expression constructs
RS65241B1 (sr) 2017-02-28 2024-03-29 Univ Pennsylvania Vektor adeno-asociranih virusa (aav) iz podgrupe f i njegove upotrebe
JOP20190200A1 (ar) 2017-02-28 2019-08-27 Univ Pennsylvania تركيبات نافعة في معالجة ضمور العضل النخاعي
TW201837170A (zh) 2017-02-28 2018-10-16 賓州大學委員會 新穎ａａｖ媒介的流感疫苗
KR20200067195A (ko) 2017-10-18 2020-06-11 리젠엑스바이오 인크. 완전-인간 번역후 변형된 항체 치료제
MX2020003945A (es) 2017-10-18 2020-11-09 Regenxbio Inc Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente .
US12558434B2 (en) 2018-02-20 2026-02-24 The Trustees Of The University Of Pennsylvania Compositions for treatment of wet age-related macular degeneration
EP4667578A3 (en) 2019-04-03 2026-04-01 REGENXBIO Inc. Gene therapy for eye pathologies
US20220195462A1 (en) 2019-04-24 2022-06-23 Regenxbio Inc. Fully-human post-translationally modified antibody therapeutics
CA3149401A1 (en) 2019-08-26 2021-03-04 Stephen Joseph Pakola Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab
WO2021071835A1 (en) 2019-10-07 2021-04-15 Regenxbio Inc. Adeno-associated virus vector pharmaceutical composition and methods
US20250326861A1 (en) 2020-09-15 2025-10-23 Regenxbio Inc. Vectorized lanadelumab and administration thereof
EP4214242A1 (en) 2020-09-15 2023-07-26 RegenxBio Inc. Vectorized antibodies for anti-viral therapy
JP2023544803A (ja) 2020-10-07 2023-10-25 レジェンクスバイオ インコーポレーテッド Ｃｌｎ２疾患の眼症状に対する遺伝子療法
WO2022094157A1 (en) 2020-10-28 2022-05-05 Regenxbio Inc. Vectorized anti-cgrp and anti-cgrpr antibodies and administration thereof
AU2021371307A1 (en) 2020-10-28 2023-06-01 Regenxbio, Inc. VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS
KR20230098176A (ko) 2020-10-29 2023-07-03 리젠엑스바이오 인크. 안구 적응증을 위한 벡터화된 tnf-알파 길항제
US20230390418A1 (en) 2020-10-29 2023-12-07 Regenxbio Inc. Vectorized factor xii antibodies and administration thereof
AR124216A1 (es) 2020-12-01 2023-03-01 Univ Pennsylvania Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen
AU2022262771A1 (en) 2021-04-23 2023-11-02 The Trustees Of The University Of Pennsylvania Novel compositions with brain-specific targeting motifs and compositions containing same
US20240384298A1 (en) 2021-10-02 2024-11-21 The Trustees Of The University Of Pennsylvania Novel aav capsids and compositions containing same
CN119317718A (zh) 2022-01-25 2025-01-14 宾夕法尼亚州大学信托人 用于改善心脏转导和肝脏去靶向的aav衣壳
US20250249127A1 (en) 2022-04-14 2025-08-07 Regenxbio Inc. Gene therapy for treating an ocular disease
WO2023205610A2 (en) 2022-04-18 2023-10-26 Regenxbio Inc. Hybrid aav capsids
TW202417633A (zh) 2022-05-03 2024-05-01 美商銳進科斯生物股份有限公司 用於眼適應症之載體化抗TNF-α抑制劑
TW202400803A (zh) 2022-05-03 2024-01-01 美商銳進科斯生物股份有限公司 載體化抗補體抗體與補體劑及其投與
EP4593955A1 (en) 2022-09-30 2025-08-06 RegenxBio Inc. Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab
EP4634394A2 (en) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2024238867A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized anti-complement antibodies and administration thereof
WO2024238859A1 (en) 2023-05-16 2024-11-21 Regenxbio Inc. Vectorized c5 inhibitor agents and administration thereof
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
WO2025102034A1 (en) 2023-11-10 2025-05-15 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome
KR20260114566A (ko) 2023-11-14 2026-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도
WO2025217230A1 (en) 2024-04-08 2025-10-16 Regenxbio Inc. Vectorized anti-complement antibodies and complement agents and administration thereof
WO2026122921A1 (en) 2024-12-05 2026-06-11 The Trustees Of The University Of Pennsylvania Gene therapy for barth syndrome

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215909A (en) * 1986-06-18 1993-06-01 Yeda Research & Development Co., Ltd. Human cholinesterase genes
ES2152920T3 (es) * 1990-02-09 2001-02-16 Salk Inst For Biological Studi Composiciones receptoras de retinoides y metodos.
PT672141E (pt) * 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5573925A (en) * 1994-11-28 1996-11-12 The Wistar Institute Of Anatomy And Biology P53 proteins with altered tetramerization domains
EP0854921A1 (en) * 1995-09-26 1998-07-29 Novartis AG GENE THERAPY WITH MODIFIED p65 PROTEINS
US5925523A (en) * 1996-08-23 1999-07-20 President & Fellows Of Harvard College Intraction trap assay, reagents and uses thereof

Also Published As

Publication number Publication date
EP1017829A2 (en) 2000-07-12
CA2300376A1 (en) 1999-03-04
AU9036198A (en) 1999-03-16
US6117680A (en) 2000-09-12
WO1999010510A3 (en) 1999-07-08
WO1999010510A2 (en) 1999-03-04

Similar Documents

Publication Publication Date Title
US6117680A (en) Compositions and methods for regulation of transcription
US6479653B1 (en) Compositions and method for regulation of transcription
AU752129B2 (en) Chimeric transcriptional activators and compositions and uses related thereto
US7109317B1 (en) FK506-based regulation of biological events
US20010049144A1 (en) Methods for high level expression of genes in primates
JP2002508971A (ja) 多量体キメラ蛋白質を使用する生物学的イベントの調節
US5919667A (en) Modular assembly retroviral vectors and uses thereof
JP2024043538A (ja) Ｂ型肝炎ワクチンおよびその使用
US6566073B1 (en) Materials and methods involving conditional retention domains
JP2004500884A (ja) 遺伝子発現の調節方法及び手段
JP2002529081A (ja) 生物学的事象のｆｋ５０６に基づく調節
JP2002535959A (ja) 条件保持ドメインを含む材料および方法
JP2002507384A (ja) アデノウイルスベクターの製造方法、それによって製造したベクターおよびその使用
WO2001098507A1 (en) Chimeric hsf transcription factors
AU5618200A (en) Chimeric oca-b transcription factors
JP2002535958A (ja) 条件集合ドメインに関する材料および方法
US20040265288A1 (en) New applications of gene therapy technology

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20050826

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050826

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20081216